Our Pipeline

Our pipeline is anchored by telitacicept, a potential best- and first-in-class therapy for generalized myasthenia gravis and other autoimmune diseases.

Vor Bio

Recruitment Region
Modality
TACI-Fc fusion protein targeting BAFF/APRIL
Indication
Myasthenia Gravis (MG)
Phase 1
Phase 2
Phase 3
Marketing Approval
Phase 3
Recruitment Region
Modality
TACI-Fc fusion protein targeting BAFF/APRIL
Indication
Primary Sjögren’s Disease (pSD)
Phase 1
Phase 2
Phase 3
Marketing Approval
Phase 3 Ready

Remegen

Recruitment Region
Modality
TACI-Fc fusion protein targeting BAFF/APRIL
Indication
Systemic Lupus Erythematosus (SLE)
Phase 1
Phase 2
Phase 3
Marketing Approval
China Marketed
Recruitment Region
Modality
TACI-Fc fusion protein targeting BAFF/APRIL
Indication
Rheumatoid Arthritis (RA)
Phase 1
Phase 2
Phase 3
Marketing Approval
China Marketed
Recruitment Region
Modality
TACI-Fc fusion protein targeting BAFF/APRIL
Indication
Myasthenia Gravis (MG)
Phase 1
Phase 2
Phase 3
Marketing Approval
China Marketed
Recruitment Region
Modality
TACI-Fc fusion protein targeting BAFF/APRIL
Indication
IgA Nephropathy (IgAN)
Phase 1
Phase 2
Phase 3
Marketing Approval
BLA Submitted
Recruitment Region
Modality
TACI-Fc fusion protein targeting BAFF/APRIL
Indication
Primary Sjögren’s Disease (pSD)
Phase 1
Phase 2
Phase 3
Marketing Approval
BLA Submitted
Recruitment Region
Modality
TACI-Fc fusion protein targeting BAFF/APRIL
Indication
Neuromyelitis Optica Spectrum Disorder (NMSOD)
Phase 1
Phase 2
Phase 3
Marketing Approval
Phase 3
Recruitment Region
Modality
TACI-Fc fusion protein targeting BAFF/APRIL
Indication
Lupus Nephritis (LN)
Phase 1
Phase 2
Phase 3
Marketing Approval
Phase 2
Recruitment Region
Modality
TACI-Fc fusion protein targeting BAFF/APRIL
Indication
Membranous Nephritis (MN) and Other Indications
Phase 1
Phase 2
Phase 3
Marketing Approval
Phase 2